Indoco Remedies share price today

Indoco Remedies Ltd's share price was ₹213.43 at the close on 4 November 2026. It has been rising for 9 weeks. That is 9.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹173 and ₹263, and at that close it sat 45% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Indoco Remedies Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 4 weeks in a row.

Over the last 11 years the share price moved −24% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Two changes stood out: revenue up on a year earlier for 6 quarters in a row and highest quarterly revenue in 16 quarters.

1. Revenue up on a year earlier for 6 quarters in a row

   In the September 2026 quarter revenue was ₹520 crore, +7.2% on a year earlier.

   Why: Revenue rose because sales to regulated international markets grew steadily, led by Europe and the US.

   Next results: check whether domestic sales recover in the second half as the call expected.

   From the earnings call on 27 Oct 2026.

2. Highest quarterly revenue in 16 quarters

   Revenue of ₹520 crore in the September 2026 quarter is the highest of the last 16 quarters.

   Why: The quarter was the highest in 16 quarters because sales to regulated international markets grew strongly, led by Europe and the US.

   Next results: check whether regulated market orders stay steady.

   From the earnings call on 27 Oct 2026.

For July to September 2026 (the quarter ended 30 September 2026), Indoco Remedies reported revenue of ₹520 crore, up 7.2% from ₹485 crore a year earlier, and a profit of ₹19.0 crore, against a loss of ₹9.00 crore a year earlier.

Indoco Remedies results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Indoco Remedies' management discussed these results on a call held on 27 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Indoco Remedies closed at ₹213.43 on 4 November 2026, down 18.2% from ₹260.95 a year earlier (7 November 2025) and down 53.0% over five years. Its highest weekly close since March 2016 was ₹481.40 on 17 September 2021.

Indoco Remedies share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

561 weekly closes from 11 March 2016 to 4 November 2026.

4 Nov 2026: Indoco Remedies closed at ₹213.43, up 2.5% on the week and down 15.2% on the month. 27 Oct 2026: Indoco Remedies held its results call for July to September 2026. Management guided: Domestic high-single-digit growth in FY27.

Earlier

• Results for July to September 2026: Revenue up 7.2% on a year earlier.
• 10 Sep 2026: ex-date for a dividend of ₹0.20 a share.

Indoco Remedies paid ₹0.20 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.09% at the ₹213.43 close on 4 November 2026. The last was a dividend of ₹0.20 a share, ex-date 10 September 2026.

Indoco Remedies dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Not in its latest year. Indoco Remedies Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 10 of its last 13 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 27 October 2026, Indoco Remedies' management guided: Domestic high-single-digit growth in FY27.

“Cyclopam has further strengthened its position as a flagship brand, crossing the 200-crore threshold and now at sales of 206 crore, while maintaining its number two position in the antispasmodics and anticholinergics market.”Aditi Panandikar, on the call for July to September 2026

What management guided

• Regulated growth above 20% over next 2-3 years.
• Total international decent double-digit growth in FY27 on Q4 strength.
• R and D at or below 5% of topline in FY27.
• PPE capital spending below ₹25 crore in FY27 with no major spend into next year.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 27 October 2026.

When Indoco Remedies reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Sterile site readout outcome clearing overhang awaited - per submitted response confidence and procedure-only view.

Indoco Remedies is on one of our India lists: Pharma stocks.

Indoco Remedies Ltd earned ₹19.0 Cr of net profit in the Sep 2026 quarter. The full FY26 year was a loss of ₹99.0 Cr. That is 3.7% of the quarter's revenue. The same quarter a year earlier lost ₹9.0 Cr. 7 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Indoco Remedies Ltd reported ₹520 Cr of revenue in the Sep 2026 quarter, +7.2% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 10 years it has grown 6.3% a year on average. The last full year, FY26, came in at ₹1,845 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹1,909 Cr.

FY26 revenue was ₹1,845 Cr, +10.8% on the year before.

Recent pace: the last four quarters grew +11.0% on average, against 6.3% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +10.6%, against +3.8% a year over the last 8 quarters (accelerating).

Indoco Remedies Ltd's operating margin was 9.0% in the Sep 2026 quarter, about the same as the same quarter a year ago. Across 13 years it has been between 6.0% and 21.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.0 percentage points on the year while gross margin changed −4.6 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 129% of Indoco Remedies Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹192 Cr of operating cash against −₹99.0 Cr of profit. After ₹91.0 Cr of spending on assets, ₹101 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 129% of profit came in as cash: the cash cycle got 35 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: the bigger use of cash is spending on new assets, at 2.5× depreciation over three years. The next section checks what that spending is building.

Indoco Remedies Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 162 days in FY26, down from 197 days in FY21. It spent ₹823 Cr on assets over the last 3 years. Customers take 97 days to pay, and stock sits for 273 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹1,845 Cr, each day of that cycle ties up about ₹5.1 Cr, so roughly ₹819 Cr is tied up in the business at any time.

FY26: customers took 97 days to pay and stock sat for 273 days, about 9.0 months of sales sitting as stock, for a full cycle of 162 days, shorter than FY21's 197.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 273 days. Customers pay about 97 days after that. Suppliers are paid at 208 days. Together that makes the 162-day cycle.

Spending on assets: ₹823 Cr over the last 3 years, against ₹332 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹90.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Indoco Remedies Ltd's P/E is 125.4×, about the highest it has ever been. Its usual P/E (the middle reading) is 31.8×, over 8.8 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.